All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-07-18T13:32:10.000Z

EHA 2018 | Atezolizumab plus R-CHOP in previously untreated DLBCL

Jul 18, 2018
Share:

Bookmark this article

On Saturday 16th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S803 was presented by Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US, on the efficacy and safety of atezolizumab plus R-CHOP.

The results of the interim analysis were presented of a phase I/II study on the use of atezolizumab, an anti-PD-L1 antibody, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) (NCT02596971). The primary endpoint was complete response (CR) by PET-CT and safety. The secondary endpoints were objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) by investigator assessment and MRD.

Study Overview

  • 42 patients were inducted and included in the interim safety analysis and 15 patients completed the induction and were included in the interim efficacy analysis
  • The ORR at the end of induction (n = 15), was 87% as per the modified Lugano 2014 and Cheson 2007 by both the independent review committee and investigator assessment
  • MRD was evaluated at 10-5 sensitivity using Adaptive ImmunoSEQ® NGS platform (v2). 15 patient samples were collected at baseline and it was found that 5 patients were MRD negative at the end of induction
  • At induction, adverse events (AEs) Grade 3-4 occurred in 64% and at consolidation Grade 3-4 AEs occurred in 15%

Dr Younes concluded that at the interim analysis, R-CHOP with atezolizumab showed encouraging activity in patients with previously untreated DLBCL with a manageable safety profile.

  1. Younes A. Atezolizumab plus R-CHOP shows encouraging activity and acceptable toxicity in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): An interim analysis of a phase I/II study. Abstract S803. 23rd Congress of EHA, Stockholm, Sweden

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 46 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox